{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:11:37Z","timestamp":1783483897402,"version":"3.55.0"},"reference-count":27,"publisher":"FapUNIFESP (SciELO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ci\u00eanc. sa\u00fade coletiva"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p>A judicializa\u00e7\u00e3o do acesso a medicamentos de alto custo para doen\u00e7as gen\u00e9ticas raras, como a doen\u00e7a de Fabry (defici\u00eancia de alfa-galactosidase A), \u00e9 um fen\u00f4meno crescente e pouco estudado de forma sistem\u00e1tica. Realizou-se um estudo observacional, transversal e retrospectivo para caracterizar as a\u00e7\u00f5es judiciais relativas ao acesso ao tratamento da doen\u00e7a de Fabry por terapia de reposi\u00e7\u00e3o enzim\u00e1tica no estado do Rio Grande do Sul at\u00e9 2007. Foram identificadas 13 a\u00e7\u00f5es e 17 demandantes. Onze solicitaram alfa e 6 betagalsidase. Figuraram como r\u00e9us o estado do RS, a Uni\u00e3o e 5 munic\u00edpios, em litiscons\u00f3rcio ou n\u00e3o. Houve 13 pedidos de antecipa\u00e7\u00e3o da tutela, 12 concedidos, e 2 senten\u00e7as, ambas procedentes. \"Risco de morte\" foi alegado, por m\u00e9dicos, em 4 prescri\u00e7\u00f5es e, por advogados, nas 13 a\u00e7\u00f5es. Os dados sugerem a aus\u00eancia de discuss\u00f5es que envolvam conjuntamente aspectos de efic\u00e1cia e seguran\u00e7a m\u00e9dicas, custo-efetividade, impacto econ\u00f4mico e argumentos jur\u00eddico-constitucionais, sendo necess\u00e1ria uma pol\u00edtica espec\u00edfica para doen\u00e7as gen\u00e9ticas raras que padronize o acesso aos tratamentos.<\/jats:p>","DOI":"10.1590\/s1413-81232012001000020","type":"journal-article","created":{"date-parts":[[2012,10,24]],"date-time":"2012-10-24T06:41:35Z","timestamp":1351060895000},"page":"2717-2728","source":"Crossref","is-referenced-by-count":18,"title":["Judicializa\u00e7\u00e3o do acesso ao tratamento de doen\u00e7as gen\u00e9ticas raras: a doen\u00e7a de Fabry no Rio Grande do Sul"],"prefix":"10.1590","volume":"17","author":[{"given":"Dailor","family":"Sartori Junior","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Gilberto Cogo","family":"Leivas","sequence":"additional","affiliation":[{"name":"Centro Universit\u00e1rio Ritter dos Reis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica Vinhas de","family":"Souza","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara Corr\u00eaa","family":"Krug","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Balbinotto","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Vanessa Doederlein","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick RJ","year":"2003","journal-title":"Ann Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot KD","year":"2001","journal-title":"J Med Genet","ISSN":"https:\/\/id.crossref.org\/issn\/0022-2593","issn-type":"print"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1590\/S1413-81232010000900019","article-title":"Medicamentos de alto custo para doen\u00e7as raras no Brasil: o exemplo das doen\u00e7as lisoss\u00f4micas","volume":"15","author":"Souza MV","year":"2010","journal-title":"Cien Saude Colet"},{"key":"ref4","series-title":"Lysosomal disorders of the brain","first-page":"50","volume-title":"Clinical aspects and diagnosis","author":"Wraith JE","year":"2004"},{"key":"ref5","series-title":"Portaria GM\/MS n\u00ba 2.577 de 27 de outubro de 2006: Aprova o Componente de Medicamentos de Dispensa\u00e7\u00e3o Excepcional","year":"2006"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1590\/S1413-81232003000200014","article-title":"Avalia\u00e7\u00e3o tecnol\u00f3gica e an\u00e1lise custo-efetividade em sa\u00fade: a incorpora\u00e7\u00e3o de tecnologias e a produ\u00e7\u00e3o de diretrizes cl\u00ednicas para o SUS","volume":"8","author":"Silva L","year":"2003","journal-title":"Cien Saude Colet"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJMp058317","article-title":"Focus on Research: Adopting Orphan Drugs - Two Dozen Years of Treating Rare Diseases","volume":"354","author":"Haffner ME","year":"2006","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref8","series-title":"Lei n\u00ba 8.080 de 19 de setembro de 1990. Disp\u00f5e sobre as condi\u00e7\u00f5es para a promo\u00e7\u00e3o, prote\u00e7\u00e3o e recupera\u00e7\u00e3o da sa\u00fade, a organiza\u00e7\u00e3o e o funcionamento dos servi\u00e7os correspondentes e d\u00e1 outras provid\u00eancias","year":"1990"},{"key":"ref9","series-title":"O Minist\u00e9rio P\u00fablico e a judicializa\u00e7\u00e3o da pol\u00edtica: estudos de casos","author":"Casagrande C","year":"2008"},{"key":"ref10","series-title":"A judicializa\u00e7\u00e3o da pol\u00edtica e das rela\u00e7\u00f5es sociais no Brasil","author":"Vianna LW","year":"1999"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A- replacement therapy in Fabry's disease","volume":"345","author":"Eng CM","year":"2001","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"21","key":"ref12","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann R","year":"2001","journal-title":"Jama","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase-Therapy in Patients with Fabry Disease","volume":"18","author":"Germain D P","year":"2007","journal-title":"J Am Soc Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/1046-6673","issn-type":"print"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/08860220903150296","article-title":"Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience","volume":"31","author":"Thofehrn S","year":"2009","journal-title":"Ren Fail","ISSN":"https:\/\/id.crossref.org\/issn\/0886-022X","issn-type":"print"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","article-title":"Agalsidase alfa slows the decline in renal function in patients with Fabry disease","volume":"29","author":"Feriozzi S","year":"2009","journal-title":"Am J Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/0250-8095","issn-type":"print"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann F","year":"2009","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"issue":"13","key":"ref17","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","article-title":"Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study","volume":"95","author":"Imbriaco M","year":"2009","journal-title":"Heart","ISSN":"https:\/\/id.crossref.org\/issn\/1355-6037","issn-type":"print"},{"issue":"17","key":"ref18","first-page":"2420","article-title":"Evidence-based medicine","volume":"268","year":"1992","journal-title":"A new approach to teaching the practice of medicine. Jama"},{"key":"ref19","series-title":"Protocolos Cl\u00ednicos e Diretrizes Terap\u00eauticas - Medicamentos Excepcionais","year":"2002"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1590\/S0034-89102000000500018","article-title":"Avalia\u00e7\u00e3o de programas, servi\u00e7os e tecnologias em sa\u00fade","volume":"34","author":"Novaes HMD","year":"2000","journal-title":"Rev Saude Publica","ISSN":"https:\/\/id.crossref.org\/issn\/0034-8910","issn-type":"print"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S026646230605077X","article-title":"Equity-efficiency trade-offs in Health Technology Assessment","volume":"22","author":"Williams AH","year":"2006","journal-title":"Int J Technol Assess Health Care","ISSN":"https:\/\/id.crossref.org\/issn\/0266-4623","issn-type":"print"},{"key":"ref22","series-title":"Portaria GM\/MS n\u00ba 2.981, de 26 de novembro de 2009. Aprova o Componente Especializado da Assist\u00eancia Farmac\u00eautica","year":"2009"},{"key":"ref23","series-title":"Lei n\u00ba 12.401. Altera a Lei n\u00ba 8.080, de 19 de setembro de 1990, para dispor sobre a assist\u00eancia terap\u00eautica e a incorpora\u00e7\u00e3o de tecnologia em sa\u00fade no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS","year":"2011"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1590\/S0102-311X2005000200019","article-title":"Mandados judiciais como ferramenta para garantia do acesso a medicamentos no setor p\u00fablico: a experi\u00eancia do Estado do Rio de Janeiro, Brasil","volume":"21","author":"Messeder AM","year":"2005","journal-title":"Cad Saude P\u00fablica"},{"issue":"20","key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10200","article-title":"A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1","volume":"10","author":"Connock M","year":"2006","journal-title":"Health Technol Assess","ISSN":"https:\/\/id.crossref.org\/issn\/1366-5278","issn-type":"print"},{"issue":"17","key":"ref26","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1001\/jama.1992.03490170092032","article-title":"Evidence-based medicine: a new approach to teaching the practice of medicine","volume":"268","year":"1992","journal-title":"Jama","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0163278710373980","article-title":"A critical appraisal of standard guidelines for grading levels of evidence","volume":"33","author":"Gugiu PC","year":"2010","journal-title":"Eval Health Prof","ISSN":"https:\/\/id.crossref.org\/issn\/0163-2787","issn-type":"print"}],"container-title":["Ci\u00eancia &amp; Sa\u00fade Coletiva"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/csc\/v17n10\/20.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T06:07:47Z","timestamp":1495865267000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1413-81232012001000020&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1413-81232012001000020"],"URL":"https:\/\/doi.org\/10.1590\/s1413-81232012001000020","relation":{},"ISSN":["1413-8123"],"issn-type":[{"value":"1413-8123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}